Clinical trials: Viral Pneumonia
SARS CoV 2 Infection
A Phase IIb/III Clinical Trial to Assess Safety and Immunogenicity of a COVID-19 Vaccine Booster Dose in Immunosupressed Adults.
A phase IIb/III, open label, single arm, multi-centre, trial to assess the immunogenicity and safety of an additional dose vaccination with a recombinant protein RBD fusion heterodimer candidate (PHH-1V) against SARS-CoV-2, in…
- Trial name
- NCT05303402
- Testing
- PHH-1V
- Where
- 6 sites in Spain, Turkey (Türkiye)
- Volunteers
- 241 people
- Sponsor
- Hipra Scientific, S.L.U
SARS-COV2, COVID19
Identifying Functional and Psycho-social Complaints After Hospitalization for SARS-CoV-2 Infection( COVID 19)- REPERCOV
Since December 2019, China and then the rest of the world have been affected by the rapid spread of a new coronavirus infection called SARS-CoV-2 (severe acute respiratory syndrome coronavirus), the clinical expression of which…
- Trial name
- REPERCOV (NCT04561154)
- Testing
- questionnaire
- Where
- France
- Volunteers
- 134 people
- Sponsor
- Centre Hospitalier le Mans
SARS-CoV2 Infection, Proximal Tubule Dysfunction
Analysis of SARS-CoV2 Urine Viral Particles and Association With Proximal Tubular Dysfunction
The primary goal is to detect Severe Acute Respiratory Syndrome CoronaVirus 2 (SARS-CoV2) urine viral particles in patients in intensive care units, hospitalized for coronavirus Coronavirus Disease-19 (COVID-19) infection, and…
- Trial name
- CovUrinePTD (NCT04937712)
- Testing
- RT-PCR SARS-COV2 in urine
- Where
- France
- Volunteers
- 34 people
- Sponsor
- Central Hospital, Nancy, France
Viral Pneumonia, Serotonin Syndrome
Cyproheptadine in Severe COVID-19 : A Unblinded Randomized Trial
This randomized controled open label clinical trial is to evaluate the effect of Cyproheptadine on the clinical course of patients presenting a severe SARS-COV 2 pneumonia.
- Conditions
- Viral Pneumonia, Serotonin Syndrome, Platelet Dysfunction
- Trial name
- NCT04820751
- Testing
- Cyproheptadine Hydrochloride 4 MG
- Volunteers
- 200 people
- Sponsor
- Ciusss de L'Est de l'Île de Montréal
Covid19, Financial Disclosure
The Provider Insurance Revenue Study in Healthcare Providers in the United States of America
The investigators are enrolling 100 healthcare Provider volunteers (n=100) from across the United States to help to evaluate and document the financial impact of COVID-19 on Physicians and other healthcare Providers.
- Trial name
- NCT04587245
- Testing
- Online questionnaire and interviews
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- ND Sciences, LLC
Long COVID, Long Covid19
RECOVER-NEURO: Platform Protocol, Appendix_A to Measure the Effects of BrainHQ, PASC CoRE and tDCS Interventions on Long COVID Symptoms
This platform protocol is designed to be flexible so that it is suitable for a wide range of settings within health care systems, for remote settings, and in community settings where it can be integrated into COVID-19 programs…
- Conditions
- Long COVID, Long Covid19, Long Covid-19
- Trial name
- NCT05965739
- Testing
- BrainHQ/Active Comparator Activity, BrainHQ, PASC CoRE
- Where
- United States
- Volunteers
- 328 people
- Sponsor
- Duke University
Covid19
Occupational Balance, Fear and Agoraphobia
This study was planned to investigate occupational balance, fear of Covid-19 and agoraphobia in adults during the Covid-19 pandemic.
- Trial name
- OB (NCT04681261)
- Testing
- this study is not an intervention study
- Where
- Turkey (Türkiye)
- Volunteers
- 699 people
- Sponsor
- Hacettepe University
Frailty, Mortality
Determining the Prevalence of Frailty and Evaluating Its Relationship With Mortality.
Covid-19 patients admitted to the intensive care unit of Selcuk University Hospital were included in the study. Clinical frailty score was given during admission to the intensive care unit.
- Conditions
- Frailty, Mortality, COVID-19
- Trial name
- NCT06330883
- Testing
- Prognosis
- Where
- Turkey (Türkiye)
- Volunteers
- 148 people
- Sponsor
- Selcuk University
SARS-CoV 2, Infection
GLS-1200 Topical Nasal Spray to Prevent SARS-CoV-2 Infection (COVID-19)
This clinical trial will evaluate the safety, tolerability and effectiveness of topical GLS-1200 nasal spray to reduce the incidence of confirmed, symptomatic SARS-CoV-2 infection.
- Trial name
- NCT04408183
- Testing
- GLS-1200
- Where
- 3 sites in United States
- Volunteers
- 184 people, healthy volunteers welcome
- Sponsor
- GeneOne Life Science, Inc.
Long-term Consequences of COVID-19 Infection
Postoperative Outcomes of Covid-19 Patients Who Were Hospitalized in a Training and Research Hospital, Who Were Operated on Electively
The Covid-19 infection has led to global health crisis. As the number of patients recovering from Covid-19 infection increases, it is necessary to create an understanding of the health problems that concern them.
- Trial name
- NCT05372341
- Testing
- descriptive
- Where
- Turkey (Türkiye)
- Volunteers
- 1 people
- Sponsor
- Samsun University
Covid-19
Nutritional Follow up After Hospital Discharge for Coronavirus Disease-19
Coronavirus infection is responsible for muscle wasting (sarcopenia), especially during prolonged stays in intensive care. Sarcopenia, in its functional aspect also seems major in patients hospitalized for this infection, in…
- Trial name
- NutriCoviDom (NCT04451694)
- Testing
- nutritional intervention
- Where
- France
- Volunteers
- 800 people
- Sponsor
- Central Hospital, Nancy, France
COVID-19
A Phase 3b/4 Randomised Trial of 3 Doses of Protein-based Covid-19 Vaccine (SpikoGen)
This study will determine the immunogenicity of Spikogen in vaccine naïve individuals. Spikogen will be administered as two doses 1 month apart with a third booster dose either 1 or 3 months after the second dose.
- Trial name
- NCT05279456
- Testing
- Advax-CpG55.2 adjuvanted recombinant spike protein
- Where
- Australia
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Vaxine Pty Ltd
Covid-19, SARS-CoV2
SURgical Outcomes in COvid Patients - the SUROCO Multicenter Cohort Study (COVID-19)
Overall mortality of COVID-19 is variable and has been reported to be between less than 1% and 7%. Many authors around the world also reported data on hospitalization rate, need for intensive care unit (ICU) care and need for…
- Conditions
- Covid-19, SARS-CoV2, Surgery, Surgical Procedure; Complications, Late Effect of Complications
- Trial name
- SUROCO (NCT04458337)
- Where
- Canada
- Volunteers
- 318 people
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
Respiratory Tract Infections, Covid19
Vitamin D3 Supplementation to Prevent Respiratory Tract Infections
The Cooper vitamin D3 study is a randomized study investigating whether daily vitamin D3 supplementation can prevent respiratory tract infections, influenza-like illness and covid-19 in hospital workers.
- Conditions
- Respiratory Tract Infections, Covid19, Flu Like Illness
- Trial name
- NCT04596657
- Testing
- Vitamin D supplementation
- Where
- United States
- Volunteers
- 877 people, healthy volunteers welcome
- Sponsor
- The Cooper Health System
COVID-19 (Coronavirus Disease 2019)
Clinical Study of Tanshinone Capsules Against COVID-19
The variation of SARS-CoV-2 has caused many countries to face the problem of multiple outbreaks. Gene mutations can change the transmicity, pathogenicity, and immunogenicity of the virus.
- Trial name
- NCT07123701
- Testing
- Tanshinone capsules
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Liu Shuwen
COVID-19 Disease, Thromboembolism, Venous
Increased Risk of VTE and Higher Hypercoagulability in Patients Recovered in ICU and in Medical Ward for COVID-19
The aim of this study is to verify if patients admitted to hospital in a medical division and in the intensive care unit for a COVID-19 infection are at higher risk of developing a VTE complication and if they actually present an…
- Trial name
- VTE-COVID (NCT04359212)
- Testing
- thromboprophylaxis with low-molecular-weight heparin or fondaparinux
- Where
- Italy
- Volunteers
- 90 people
- Sponsor
- Quovadis Associazione
Covid19
Study to Reinforce Immunity (STRI) Phase 2 Clinical Trial
Protocol STRI12 - Study to Reinforce Immunity (STRI) - A Phase 2 Double-Blind, Randomized, Placebo-Controlled Study to Investigate the Safety and Efficacy of STRI Formula in Non-Hospitalized Participants with COVID-19 (the Study)
- Trial name
- NCT05046561
- Testing
- STRI Formula
- Where
- 13 sites in United States
- Volunteers
- 598 people
- Sponsor
- Eyecheck, Inc.
Covid19
A Trial Using ANAKINRA, TOCILIZUMAB Alone or in Association With RUXOLITINIB in Severe Stage 2b and 3 of COVID19-associated Disease
COVID19-associated disease may have different clinical aspects classified in 3 stages. Some patients initially presenting with a non-hypoxemic viral pneumonia (stage 2a) may evolve toward a more severe stage 2b or 3 (acute…
- Trial name
- INFLAMMACOV (NCT04424056)
- Testing
- Anakinra +/- Ruxolitinib (stages 2b/3), Anakinra and Ruxolitinib (Advanced stage 3), Tocilizumab +/- ruxolitinib (stages 2b/3)
- Where
- France
- Volunteers
- 216 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
COVID-19 Pneumonia, Coronavirus Infections
Clinical Trial on Sequential Immunization of Recombinant COVID-19 Vaccine (CHO Cells,NVSI-06-08) and Inactivated COVID-19 Vaccine (Vero Cells) in Population Aged 18 Years and Above
This is randomized, blinded and controlled design. Among the randomly selected subjects who have been vaccinated with two doses of Inactivated COVID-19 vaccine (Vero cell), based on a step-wise approach, the subjects will receive…
- Trial name
- NCT05069129
- Testing
- Recombinant COVID-19 Vaccine (CHO cell，NVSI-06-08), Inactivated COVID-19 vaccine (Vero cells), 3 doses Recombinant COVID-19 Vaccine (CHO cell，NVSI-06-08)
- Where
- United Arab Emirates
- Volunteers
- 1,848 people, healthy volunteers welcome
- Sponsor
- National Vaccine and Serum Institute, China
Covid-19, Cognitive Impairment
Improving Thinking in Everyday Life After Covid-19
The purpose of this initial study is to evaluate a new form of cognitive rehabilitation therapy for improving your ability to think, particularly how rapidly you process information that you receive from your senses, e.g., sight…
- Trial name
- NCT04644172
- Testing
- Speed of Processing Training, Instrumental Activities of Daily Living Shaping, Transfer Package from CI Therapy
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of Alabama at Birmingham
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.